CAMURUS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 581 SEK | +7.89% |
|
+3.66% | +7.99% |
| May. 23 | Camurus' Rare Growth Disorder Drug Accepted for Review in EU | MT |
| May. 23 | Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot for the Treatment of Acromegaly | CI |
| Sales 2024 * | 1.9B 180M | Sales 2025 * | 2.99B 284M | Capitalization | 33.48B 3.18B |
|---|---|---|---|---|---|
| Net income 2024 * | 335M 31.83M | Net income 2025 * | 978M 92.92M | EV / Sales 2024 * | 16.6 x |
| Net cash position 2024 * | 1.98B 188M | Net cash position 2025 * | 3.31B 315M | EV / Sales 2025 * | 10.1 x |
| P/E ratio 2024 * |
101
x | P/E ratio 2025 * |
34.7
x | Employees | 218 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.88% |
More Fundamentals
* Assessed data
More news
Latest transcript on Camurus AB
More press releases
More news
| 1 day | +7.89% | ||
| 1 week | +3.66% | ||
| 1 month | +16.62% | ||
| 3 months | +27.30% | ||
| 6 months | +25.81% | ||
| Current year | +7.99% |
1 week
532.50
586.00
1 month
470.40586.00
Current year
417.40599.50
1 year
259.00599.50
3 years
120.00599.50
5 years
61.50599.50
10 years
58.00599.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01-12-31 | |
| Director of Finance/CFO | 51 | 22-01-31 | |
| Chief Tech/Sci/R&D Officer | - | 23-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 09-12-31 | |
| Chief Executive Officer | 61 | 01-12-31 | |
| Director/Board Member | 52 | 20-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 581 | +7.89% | 465,226 |
| 24-05-30 | 538.5 | +0.56% | 45,390 |
| 24-05-29 | 535.5 | -1.83% | 35,441 |
| 24-05-28 | 545.5 | -0.46% | 34,146 |
| 24-05-27 | 548 | -2.23% | 26,680 |
Delayed Quote Nasdaq Stockholm, May 31, 2024 at 11:29 am EDT
More quotes
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Companyâs products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Sector
Pharmaceuticals
Calendar
2024-06-02
- BIO International Convention
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
581
SEK
Average target price
612.3
SEK
Spread / Average Target
+5.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.99% | 3.18B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- CAMX Stock
